Krystal Biotech (KRYS) Company Report

Krystal's first genetic medicine, Vyjuvek, has been launched in the U.S. for almost two years, with recent launches in France, Germany, and Japan, showing remarkable safety and efficacy in the U.S..
The company reports a very good financial position, having achieved positive EPS for the last eight to nine quarters and maintaining a strong balance sheet.
For Vyjuvek in the U.S., Krystal has identified 1,200 definitive patients and is currently treating 615, with a total estimated prevalence of 3,000 patients. Ex-U.S. sales are also progressing, with Japan's pricing close to U.S. net pricing.
Key pipeline updates include an upcoming readout for Cystic Fibrosis, an Alpha-1 Antitrypsin Deficiency repeat dosing study readout expected mid-next year, and ongoing studies for Ocular DEB and Neurotrophic Keratopathy.

1 day ago

Transcript

Krystal Biotech Provides Update on Vyjuvek Commercialization and Pipeline Progress

KRYS

Product Launch

New Projects/Investments

Guidance Update

Krystal Biotech's Vyjuvek has been launched in the U.S. for almost two years and recently in France, Germany, and Japan, with 615 out of 1,200 identified U.S. patients currently on drug.
The company projects an average price per patient for Vyjuvek in the U.S. to be $450,000-$500,000 at steady state, with annual vial consumption between 26 and 30 vials.
Krystal Biotech reports a very good financial position, having achieved positive EPS for the last eight to nine quarters and maintaining a strong balance sheet.
Key pipeline updates include a blinded study for ocular DEB and a 30-patient single registrational study for Neurotrophic Keratopathy (NK), with other programs in Cystic Fibrosis (CF), Alpha-1 Antitrypsin Deficiency (AATD), oncology, and Hailey-Hailey disease also progressing.

1 day ago

Transcript

Krystal Biotech Provides Update on VYJUVEK Launch and Pipeline

KRYS

Product Launch

New Projects/Investments

Guidance Update

Krystal Biotech's VYJUVEK, the first genetic medicine approved for at-home dosing, has been launched in the U.S. for almost two years and recently in France, Germany, and Japan. The company has reached 615 of its 1,200 identified U.S. patients and anticipates an average price per patient of $450,000-$500,000 at steady state. Outside the U.S., pricing in Japan is close to U.S. net pricing, and the company expects to break out ex-U.S. sales when they become material.
The company is in a strong financial position, having reported positive EPS for the last eight to nine quarters and maintaining a strong balance sheet.
Krystal Biotech is advancing a pipeline including programs for ocular DEB (blinded study, 100+ patients in natural history, 16 needed for main study) and NK (30-patient study), with upcoming readouts for Cystic Fibrosis (CF) and a repeat dosing study for Alpha-1 Antitrypsin Deficiency (AATD).

1 day ago

Transcript

Krystal Biotech Reports Q3 2025 Financial Results and Vyjuvek Global Expansion

KRYS

Earnings

Product Launch

Guidance Update

Krystal Biotech reported Q3 2025 net Vyjuvek revenue of $97.8 million and a 96% gross margin, with net income of $79.4 million and diluted EPS of $2.66. The company ended the quarter with over $864 million in combined cash and investments.
The company announced the global expansion of Vyjuvek with launches in Germany, France, and Japan. In the U.S., reimbursement approvals increased to over 615, and the prescriber network expanded to over 450.
Krystal Biotech updated its full-year non-GAAP R&D and SG&A guidance to $145-$155 million. Key pipeline developments include an expected readout for the CF program (KB407) before year-end, the initiation of a new clinical program for Hailey-Hailey disease (KB111), and the FDA's Platform Therapy Designation for KB801.

Nov 3, 2025, 1:30 PM

Transcript

Krystal Biotech Announces Strong Q3 2025 Results and Global VYJUVEK Expansion

KRYS

Earnings

Guidance Update

Product Launch

Krystal Biotech reported $97.8 million in net product revenue for Q3 2025, contributing to over $623 million in net VYJUVEK revenue since launch. The company's cash and investments stood at $864.2 million as of September 30, 2025, with diluted EPS at $2.66 for the quarter.
The company updated its non-GAAP combined R&D and SG&A expense guidance for Full Year 2025 to $145 million to $155 million.
Global expansion of VYJUVEK is underway with recent launches in Japan and France, a strong start in Germany, and the establishment of a specialty distributor network for other markets.
The FDA granted Platform Technology Designation for KB801, and the company is on track to report molecular data from KB407 Phase 1 for Cystic Fibrosis by year-end. Additionally, KB111 is entering the clinic for Hailey-Hailey disease, with a study planned for 1H 2026.

Nov 3, 2025, 1:30 PM

Presentation

Krystal Biotech Announces Q3 2025 Financial and Operational Results

KRYS

Earnings

Product Launch

Guidance Update

Krystal Biotech reported $97.8 million in VYJUVEK revenue for Q3 2025, contributing to a total of $623.2 million since its U.S. launch, and ended the quarter with $864.2 million in cash and investments as of September 30, 2025.
The company achieved $79.4 million in net income for Q3 2025, or $2.74 per common share (basic).
VYJUVEK expanded its global presence with launches in Germany during Q3 2025, and subsequently in France and Japan in Q4 2025.
Krystal Biotech anticipates interim results for its cystic fibrosis program (KB407) in Q4 2025 and for its alpha-1 antitrypsin deficiency program (KB408) in 1H 2026.
For FY 2025, the company projects non-GAAP Research and Development and Selling, General and Administrative expense to be between $145.0 million and $155.0 million.

Nov 3, 2025, 12:04 PM

8-K

Krystal Biotech Receives FDA Approval for Updated VYJUVEK® Label

KRYS

Product Launch

Krystal Biotech announced on September 15, 2025, that the United States Food and Drug Administration (FDA) approved a label update for VYJUVEK®.
The updated label expands the eligible patient population to include dystrophic epidermolysis bullosa (DEB) patients from birth.
This update also provides patients and caregivers full flexibility to apply VYJUVEK themselves and manage wound dressings without a 24-hour waiting period.
These changes are expected to reinforce VYJUVEK’s leadership position and improve patient compliance, solidifying it as the standard of care for DEB wounds.

Sep 15, 2025, 12:00 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Krystal Biotech.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Krish S. Krishnan say about margins?What are Krystal Biotech's strategic priorities?How is Krystal Biotech positioned vs competitors?How did Krystal Biotech do last quarter?

Let Fintool AI Agent track Krystal Biotech's earnings for you

Get instant analysis when filings drop